August 06, 2018
1 min watch

VIDEO: Luminate blocks integrin receptors, reduces oxidative stress

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

VANCOUVER, British Columbia At the American Society of Retina Specialists meeting, Peter K. Kaiser, MD, reviews differences between Luminate (risuteganib, Allegro), which decreases oxidative stress from diabetes by blocking integrin receptors, and Avastin (bevacizumab, Genentech), which works farther downstream in the oxidative pathway, at the level of inflammation and vascular permeability.